Receptor tyrosine kinases overexpressed and mutated in cancer cells have proven to be exceptionally good targets for such approaches and antibodies to the EGFR and HER2 receptors have proved very useful in the treatment of breast cancer and colon cancer21. This evidence concerns the gene NTRK1 and breast cancer.